New perspectives on the role of tau in Alzheimer's disease. Implications for therapy.
Alzheimer's disease (AD) and related dementias constitute a major public health issue due to an increasingly aged population as a consequence of generally improved medical care and demographic changes. Current drug treatment of AD, the most prevalent dementia, with cholinesterase inhibitors or NMDA antagonists have demonstrated very modest, symptomatic efficacy, leaving an unmet medical need for new, more effective therapies. While drug development efforts in the last two decades have primarily focused on the amyloid cascade hypothesis, so far with disappointing results, tau-based strategies have received little attention until recently despite that the presence of extensive tau pathology is central to the disease. The discovery of mutations within the tau gene that cause fronto-temporal dementia demonstrated that tau dysfunction, in the absence of amyloid pathology, was sufficient to cause neuronal loss and clinical dementia. Abnormal levels and hyperphosphorylation of tau protein have been reported to be the underlying cause of a group of neurodegenerative disorders collectively known as 'tauopathies'. The detrimental consequence is the loss of affinity between this protein and the microtubules, increased production of fibrillary aggregates and the accumulation of insoluble intracellular neurofibrillary tangles. However, it has become clear in recent years that tau is not only a microtubule interacting protein, but rather has additional roles in cellular processes. This review focuses on emerging therapeutic strategies aimed at treating the underlying causes of the tau pathology in tauopathies and AD, including some novel approaches on the verge of providing new treatment paradigms within the coming years.
Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Valderrebollo 5, 28041 Madrid, Spain.
Miguel
M
Medina
Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Valderrebollo 5, 28041 Madrid, Spain; Centro de Biología Molecular "Severo Ochoa" CSIC-UAM, Nicolás Cabrera 1, 28049 Madrid, Spain. Electronic address: javila@cbm.uam.es.
Jesús
J
Avila
D000544:Alzheimer Disease / Q000503:physiopathology* / Q000628:therapy; D006801:Humans; D007167:Immunotherapy; D008870:Microtubules / Q000378:metabolism; D010766:Phosphorylation; D016875:tau Proteins / Q000378:metabolism / Q000502:physiology*
D016875:tau Proteins
Alzheimer; Dementia; Immunotherapy; Tau; Tauopathies; Therapy